Diseases /
Melanoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain. [1]
Biomarker-Directed Therapies
Of the biomarker-directed therapies for melanoma, 7 are FDA-approved in at least one setting and 9 have NCCN guidelines in at least one setting [3].
Binimetinib +
Disease is predicted to be sensitive: -
| Biomarker Criteria: | Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended for NRAS mutated tumors that have progressed after prior immune checkpoint inhibitor therapy (category 2B). |
Dabrafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NICE, BNF, SMC) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NICE, SMC) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy with dabrafenib is recommended, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Encorafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Imatinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: |
Clinical Setting(s): Metastatic (NCCN, MCG) |
Nilotinib +
Disease is predicted to be sensitive: -
Sorafenib +
Sunitinib +
Trametinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Trametinib is FDA approved for single-agent use to treat patients with unresectable or metastatic melanoma with BRAF V600E/K; however, trametinib monotherapy is no longer an NCCN-recommended treatment option due to relatively poor efficacy compared with BRAF inhibitor monotherapy and BRAF/MEK inhibitor combination therapy. |
Vemurafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, if BRAF/MEK inhibitor combination therapy is contraindicated, BRAF-inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy. |
Atezolizumab + Cobimetinib + Vemurafenib +
Disease is predicted to be sensitive: -
Binimetinib + Encorafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: Approved for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: Recommended by NCCN if a BRAF V600 activating mutation is present. |
Cobimetinib + Vemurafenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA, NCCN) |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity |
Dabrafenib + Pembrolizumab + Trametinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (NCCN) |
| Note: NCCN recommended as first line therapy (Category 2B). |
Dabrafenib + Trametinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) |
| Note: According to NCCN, BRAF/MEK inhibitor combination is preferred over BRAF inhibitor monotherapy based on results from phase III trials in the first-line setting showing improved outcomes and similar risk of toxicity. |
Clinical Trials
There are 472 clinical trials for melanoma, of which 334 are open and 138 are completed or closed. Of the trials that contain melanoma as an inclusion criterion, 8 are early phase 1 (6 open), 174 are phase 1 (117 open), 110 are phase 1/phase 2 (83 open), 153 are phase 2 (110 open), 3 are phase 2/phase 3 (3 open), 18 are phase 3 (10 open), 1 is phase 4 (1 open), and 5 are no phase specified (4 open).
BRAF, HLA-A*02, and KIT are the most frequent gene inclusion criteria for melanoma clinical trials [3].
Pembrolizumab, nivolumab, and ipilimumab are the most common interventions in melanoma clinical trials.
Significant Genes in Melanoma
ABL1 +
ABL1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains ABL1 status and melanoma as inclusion criteria, 1 is no phase specified (0 open) [3].
ABL2 +
ABL2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ACVR1B +
ACVR1B is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
AKT1 +
AKT1 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain AKT1 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
AKT2 +
AKT2 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain AKT2 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
AKT3 +
AKT3 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
ALK +
ALK is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 5 are open and 1 is closed. Of the trials that contain ALK status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 5 are phase 2 (4 open) [3].
APC +
APC is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ARAF +
ARAF is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain ARAF status and melanoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 1/phase 2 (2 open) [3].
ARID1A +
ARID1A is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
ARID1B +
ARID1B is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1B status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
ARID2 +
ARID2 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain ARID2 status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
ASXL1 +
ASXL1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
ATM +
ATM is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain ATM status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [3].
ATR +
ATR is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain ATR status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [3].
ATRX +
ATRX is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
BAP1 +
BAP1 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain BAP1 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [3].
BARD1 +
BARD1 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
BCR +
BCR is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains BCR status and melanoma as inclusion criteria, 1 is no phase specified (0 open) [3].
BLM +
BLM is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain BLM status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
BRAF +
BRAF is an inclusion eligibility criterion in 106 clinical trials for melanoma, of which 59 are open and 47 are closed. Of the trials that contain BRAF status and melanoma as inclusion criteria, 2 are early phase 1 (2 open), 32 are phase 1 (15 open), 20 are phase 1/phase 2 (12 open), 46 are phase 2 (26 open), and 6 are phase 3 (4 open) [3].
Dabrafenib, vemurafenib, binimetinib, encorafenib, cobimetinib, trametinib, atezolizumab, and pembrolizumab have evidence of efficacy in patients with BRAF mutation in melanoma [3].
BRCA1 +
BRCA1 is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [3].
BRCA2 +
BRCA2 is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [3].
BRIP1 +
BRIP1 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain BRIP1 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [3].
BTRC +
BTRC is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
C11ORF30 +
C11orf30 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CCND1 +
CCND1 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain CCND1 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [3].
CDK12 +
CDK12 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 2 are open and 1 is closed. Of the trials that contain CDK12 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].
CDK4 +
CDK4 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain CDK4 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [3].
CDK6 +
CDK6 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
CDKN1A +
CDKN1A is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
CDKN1B +
CDKN1B is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
CDKN2A +
CDKN2A is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain CDKN2A status and melanoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
CHD4 +
CHD4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
CHEK1 +
CHEK1 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK1 status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
CHEK2 +
CHEK2 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain CHEK2 status and melanoma as inclusion criteria, 4 are phase 2 (4 open) [3].
CRKL +
CRKL is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain CRKL status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [3].
CSF1R +
CSF1R is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
CYLD +
CYLD is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
CYSLTR2 +
CYSLTR2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains CYSLTR2 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
DICER1 +
DICER1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DNMT3A +
DNMT3A is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
DVL1 +
DVL1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
EGFR +
EGFR is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain EGFR status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 2 (3 open) [3].
EPCAM +
EPCAM is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 3 are open and 3 are closed. Of the trials that contain ERBB2 status and melanoma as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (2 open) [3].
ERBB3 +
ERBB3 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
ERCC3 +
ERCC3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
EXO1 +
EXO1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
EZH2 +
EZH2 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain EZH2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [3].
FANCA +
FANCA is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain FANCA status and melanoma as inclusion criteria, 4 are phase 2 (4 open) [3].
FANCB +
FANCB is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCC +
FANCC is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCD2 +
FANCD2 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain FANCD2 status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
FANCE +
FANCE is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCF +
FANCF is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCG +
FANCG is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCI +
FANCI is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCL +
FANCL is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCM +
FANCM is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FGFR1 +
FGFR1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FGFR2 +
FGFR2 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
FGFR3 +
FGFR3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT1 +
FLT1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT3 +
FLT3 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
FLT4 +
FLT4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FZD1 +
FZD1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD10 +
FZD10 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD2 +
FZD2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD3 +
FZD3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD4 +
FZD4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD5 +
FZD5 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD6 +
FZD6 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD7 +
FZD7 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD8 +
FZD8 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD9 +
FZD9 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
GATA3 +
GATA3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
GNA11 +
GNA11 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain GNA11 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
GNAQ +
GNAQ is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain GNAQ status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
HGF +
HGF is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
HRAS +
HRAS is an inclusion eligibility criterion in 9 clinical trials for melanoma, of which 7 are open and 2 are closed. Of the trials that contain HRAS status and melanoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
IDH1 +
IDH1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KDM6A +
KDM6A is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KDR +
KDR is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
KEAP1 +
KEAP1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KIT +
KIT is an inclusion eligibility criterion in 13 clinical trials for melanoma, of which 7 are open and 6 are closed. Of the trials that contain KIT status and melanoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (4 open), and 1 is phase 3 (0 open) [3].
Imatinib, nilotinib, sorafenib, and sunitinib have evidence of efficacy in patients with KIT mutation in melanoma [3].
KMT2D +
KMT2D is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
KRAS +
KRAS is an inclusion eligibility criterion in 12 clinical trials for melanoma, of which 9 are open and 3 are closed. Of the trials that contain KRAS status and melanoma as inclusion criteria, 9 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
LIG3 +
LIG3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains LIG3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
LIG4 +
LIG4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains LIG4 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
LRP5 +
LRP5 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
LRP6 +
LRP6 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
MAGI2 +
MAGI2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
MAP2K1 +
MAP2K1 is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 5 are open and 1 is closed. Of the trials that contain MAP2K1 status and melanoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
MAP2K2 +
MAP2K2 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MAP2K2 status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
MAP2K4 +
MAP2K4 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MAP2K4 status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
MAP3K1 +
MAP3K1 is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain MAP3K1 status and melanoma as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
MAPK1 +
MAPK1 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MAPK1 status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MDC1 +
MDC1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains MDC1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MED12 +
MED12 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
MET +
MET is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 3 are open and 2 are closed. Of the trials that contain MET status and melanoma as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 2 (2 open) [3].
MLH1 +
MLH1 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain MLH1 status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
MLH3 +
MLH3 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain MLH3 status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
MRE11A +
MRE11A is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MRE11A status and melanoma as inclusion criteria, 4 are phase 2 (4 open) [3].
MSH2 +
MSH2 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain MSH2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
MSH3 +
MSH3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MSH6 +
MSH6 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
MST1R +
MST1R is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
MTOR +
MTOR is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain MTOR status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
MYC +
MYC is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
MYCN +
MYCN is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].
NBN +
NBN is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain NBN status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [3].
NF1 +
NF1 is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 5 are open and 1 is closed. Of the trials that contain NF1 status and melanoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
NF2 +
NF2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NOTCH1 +
NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NOTCH2 +
NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NRAS +
NRAS is an inclusion eligibility criterion in 18 clinical trials for melanoma, of which 9 are open and 9 are closed. Of the trials that contain NRAS status and melanoma as inclusion criteria, 11 are phase 1 (6 open), 5 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [3].
Binimetinib has evidence of efficacy in patients with NRAS mutation in melanoma [3].
NRG1 +
NRG1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
NSD1 +
NSD1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
NTRK1 +
NTRK1 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain NTRK1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [3].
NTRK2 +
NTRK2 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 2 are open and 1 is closed. Of the trials that contain NTRK2 status and melanoma as inclusion criteria, 3 are phase 2 (2 open) [3].
NTRK3 +
NTRK3 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 2 are open and 1 is closed. Of the trials that contain NTRK3 status and melanoma as inclusion criteria, 3 are phase 2 (2 open) [3].
PALB2 +
PALB2 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain PALB2 status and melanoma as inclusion criteria, 4 are phase 2 (4 open) [3].
PARP1 +
PARP1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PCNA +
PCNA is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PDGFRA +
PDGFRA is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain PDGFRA status and melanoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
PDGFRB +
PDGFRB is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PIK3C2B +
PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PIK3CA +
PIK3CA is an inclusion eligibility criterion in 5 clinical trials for melanoma, of which 3 are open and 2 are closed. Of the trials that contain PIK3CA status and melanoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
PIK3CB +
PIK3CB is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
PIK3CG +
PIK3CG is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CG status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
PIK3R1 +
PIK3R1 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 2 are open and 1 is closed. Of the trials that contain PIK3R1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [3].
PIK3R2 +
PIK3R2 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R2 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
PLCB4 +
PLCB4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PLCB4 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
PMS1 +
PMS1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PMS2 +
PMS2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
POLD1 +
POLD1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
POLE +
POLE is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PRKDC +
PRKDC is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PRKDC status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
PTCH1 +
PTCH1 is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain PTCH1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].
PTEN +
PTEN is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 4 are open and 2 are closed. Of the trials that contain PTEN status and melanoma as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [3].
PTPN11 +
PTPN11 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
RAD50 +
RAD50 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain RAD50 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [3].
RAD51 +
RAD51 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [3].
RAD51B +
RAD51B is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAD51C +
RAD51C is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
RAD51D +
RAD51D is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAD54B +
RAD54B is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54B status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [3].
RAD54L +
RAD54L is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RAF1 +
RAF1 is an inclusion eligibility criterion in 6 clinical trials for melanoma, of which 6 are open and 0 are closed. Of the trials that contain RAF1 status and melanoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].
RASA1 +
RASA1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RASA1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
RB1 +
RB1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
RET +
RET is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain RET status and melanoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].
RFC1 +
RFC1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC2 +
RFC2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC3 +
RFC3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC4 +
RFC4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RFC5 +
RFC5 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RICTOR +
RICTOR is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain RICTOR status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
RNF43 +
RNF43 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
ROS1 +
ROS1 is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain ROS1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [3].
RPA1 +
RPA1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA2 +
RPA2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA3 +
RPA3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPA4 +
RPA4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RPTOR +
RPTOR is an inclusion eligibility criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain RPTOR status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
RSPO1 +
RSPO1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
RUNX1 +
RUNX1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SETD2 +
SETD2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains SETD2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SHFM1 +
SHFM1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains SHFM1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
SLX4 +
SLX4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
SMARCA4 +
SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SMO +
SMO is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
SOS1 +
SOS1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
SOX9 +
SOX9 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
SRC +
SRC is an inclusion eligibility criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain SRC status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [3].
SSBP1 +
SSBP1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
STAG2 +
STAG2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains STAG2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
STK11 +
STK11 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TAF1 +
TAF1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TBX3 +
TBX3 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TET2 +
TET2 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TP53 +
TP53 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
TSC1 +
TSC1 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain TSC1 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
TSC2 +
TSC2 is an inclusion eligibility criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain TSC2 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
VHL +
VHL is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
WNT1 +
WNT1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [3].
XPO1 +
XPO1 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [3].
XRCC6 +
XRCC6 is an inclusion eligibility criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC6 status and melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
